ABSTRACT
INTRODUCTION
Babesia is an intraerythrocytic protozoan parasite that is transmitted to animals by ticks and babesiosis is also important with regard to zoonotic diseases. Recent our studies have shown that the use of histone deacetylase inhibitor, apicidin, can inhibit enzyme activity of recombinant B.bovis histone deacetylase protein (1) and the growth-inhibitory effect on Babesia parasites both in vitro and in vivo. (2) . Trichostatin A is one of inhibitors of histone deacetylase and has a broad spectrum of epigenetic activities. Therefore, the present study focuses on evaluation of the efficacy of Trichostatin A against B.bovis and B.bigemina for cattle, B.caballi and T.equi for horses, B.gibsoni for dogs in vitro, and B. microti for mice and humans in vivo.
MATERIALS AND METHODS
Inhibitory effects of Trichostatin A upon the B.bovis, B.bigemina, B.gibsoni, B.caballi and T.equi growth were examined as previously described (2 and 3). The in vivo growth inhibition assay for Trichostatin A (2 mg/kg) was performed in BALB/c mice as previously described (4) .
RESULTS
The growth of B.bovis, B.bigemina, B.caballi, T.equi, and B.gibsoni was significantly inhibited (P < 0.05) by Trichostatin A at concentration of 5 nM. In the presence of 25 nM of Trichostatin A, the growth of all parasites was completely suppressed on day 4. Subsequent viability tests showed that there was no re-growth of the five species of parasites at concentration of 5 nM for Trichostatin A. Moreover, Trichostatin A affected the morphology of B.bovis, B.bigemina, B.caballi, T.equi, and B.gibsoni parasites in the treated cultures.
To examine the effects of Trichostatin A on B.microti, infected mice were treated with Trichostatin A. In the treated group, levels of parasitemia were significantly lower than the control group (P < 0.05). Peak parasitemia reached an average of 21.9 % in treatment with the dose of 2 mg/kg, while in the control group it was 67.8 % (Dimethyl sylfoxid) at 8 days after inoculation. There were significant differences (P < 0.05) between the control and treated groups observed at days 6-13 post-infection. 
DISCUSSION
In this study, we conducted the first investigation of the in vitro and in vivo growth inhibition activity of histone deacetylase inhibitor, Trichostatin A, against bovine, equine, canine, and murine Babesia parasites. Exposure to higher concentrations of Trichostatin A completely suppressed the growth of bovine, equine, and canine Babesia parasites in in vitro cultures. Because treatment only with Dimethyl sylfoxid had no effect on parasitic growth, this growth inhibition of parasites was certainly due to effects of Trichostatin A. Since Trichostatin A inhibited the growth of in vitro-cultured Babesia parasites, we evaluated its inhibitory effect in an in vivo model of B. microti in BALB/c mice. No sign of toxicity was observed on treated mice. B.microti was suppressed in mice treated with Trichostatin A for 6 days at the dose of 2 mg/kg, with 78.1 % inhibition on day 8 p.i. This result is in agreement with our previous study that apicidin inhibited the growth of murine Babesia parasite in vivo (2) . Therefore, inhibitors of histone deacetylase such as Trichostatin A and apicidin at low doses are not toxic to mice and might be used for the safe treatment of babesiosis.
In conclusion, our present findings showed that the efficacy of Trichostatin A on the growth of Babesia parasites in vitro and in vivo with the absence of any toxic side effects for the first time. Therefore, Trichostatin A might be an excellent target for the development of novel anti-babesial agents.
